Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 1 1

Status

Completed 23Recruiting 19Active not recruiting 17Terminated 16Withdrawn 4Unknown 4Not yet recruiting 2Suspended 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 3Thoracic 1

Conditions

Melanoma 3Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 129Cisplatin 119Radiotherapy 115pembrolizumab 111Carboplatin 97Paclitaxel 96Gemcitabine 96Magnetic Resonance Spectroscopy 80Nivolumab 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Biopsy 53Doxorubicin 52fludarabine 51Drug Therapy 45durvalumab 44Cytarabine 44Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Surveys and Questionnaires 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Withdrawn × encorafenib × Clear all
NCT07092410 2026-04-21

SuRage-EB

SRH Wald-Klinikum Gera GmbH

Phase 4 Withdrawn
Dermatologic

Melanoma

NCT04759846 2023-02-21

Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma

Pierre Fabre Medicament

Phase 1 Withdrawn
Dermatologic

Melanoma

NCT02109653 2020-11-13

Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC

Array BioPharma

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02263898 2020-07-27

Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations

Jonsson Comprehensive Cancer Center

Phase 2 Withdrawn
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡